Will Jiang

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer

Robert Olson, Will Jiang, Mitchell Liu et al. · JAMA Oncology · 2022 · 69 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial

Sarah Baker, Will Jiang, Benjamin Mou et al. · International Journal of Radiation Oncology*Biology*Physics · 2022 · 43 citations

Medicine, Oncology, Molecular Oncology +5

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial

Reno Eufemon Cereno, Benjamin Mou, Sarah Baker et al. · Radiotherapy and Oncology · 2023 · 28 citations

Medicine, Oncology, Radiation Oncology +17

Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial

Sarah Baker, Linden Lechner, Mitchell Liu et al. · International Journal of Radiation Oncology*Biology*Physics · 2024 · 15 citations

Medicine, Oncology, Medical Oncology +6

Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial

Sarah Baker, Benjamin Mou, Will Jiang et al. · International Journal of Radiation Oncology*Biology*Physics · 2022 · 10 citations

Medicine, Oncology, Neoplasia +6